logo

For the Inventor, By the Inventor

Juechen Gierath, Germany

Torsten Dunkern

This inventor holds 6 USPTO granted patents and 2 published patent applications. Top assignee: Takeda Gmbh. Active years: 2013-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Torsten Dunkern. Retrieved from https://idiyas.com/inventor/torsten-dunkern

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

Average Co-Inventor Count = 10.1

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Volkertshausen, DE (2013)
  • Jüchen Gierath, DE (2014 - 2015)
  • Juechen Gierath, DE (2015 - 2016)
  • Juchen, DE (2016)

Company Filing History:

goldMedal6 out of 47 
 
Takeda Gmbh
 patents

Years Active: 2013-2016

Loading Chart...
6 patents (USPTO):Explore Patents
1. 9376442 - Methylpyrrolopyrimidinecarboxamides (2016-06-28),
2. 9309187 - EP2 receptor agonists (2016-04-12),
3. 9018175 - 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives (2015-04-28),
4. 8927557 - Methylpyrrolopyrimidinecarboxamides (2015-01-06),
5. 8816085 - Methylpyrrolopyridinecarboxamides (2014-08-26),
6. 8445501 - Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines (2013-05-21),

Title: The Innovative Mind of Torsten Dunkern

Introduction: Torsten Dunkern, hailing from Juechen Gierath, Germany, is a prominent inventor known for his contributions to the pharmaceutical field. With a remarkable portfolio of six patents, Dunkern has dedicated his career to developing innovative compounds that address significant medical challenges.

Latest Patents: Among his latest patents are two notable inventions. The first, related to Methylpyrrolopyrimidinecarboxamides, introduces compounds that serve as effective inhibitors of the type 5 phosphodiesterase, demonstrating potential in treating or preventing idiopathic pulmonary lung fibrosis. The second patent focuses on EP2 receptor agonists, presenting novel compounds that act as effective EP2 agonists, underscoring Dunkern's commitment to advancing therapeutic options.

Career Highlights: Torsten Dunkern currently works at Takeda GmbH, a leading global pharmaceuticals company dedicated to improving patient outcomes. His innovative spirit and extensive research have significantly contributed to the company's mission in developing groundbreaking treatments.

Collaborations: Throughout his esteemed career, Dunkern has collaborated with renowned professionals such as Josef Stadlwieser and Beate Schmidt. These collaborations reflect a synergy of expertise and creativity that fosters the development of pioneering pharmaceutical solutions.

Conclusion: Torsten Dunkern stands out as an influential inventor in the pharmaceutical industry. His ongoing work exemplifies a dedication to innovation, with a focus on creating therapies that can revolutionize patient care. As he continues to push the boundaries of science, Dunkern's impact on medicine is sure to be felt for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…